Cypherpunk Technologies Inc. (CYPH)
NASDAQ: CYPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CYPH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $210.15M
- P/E (TTM)
- 0.67
- EPS (TTM)
- $2.09
- Dividend yield
- None
- 52-week range
- 0.491 – 4.19
- Day range
- 1.37 – 1.66
- Volume / Avg
- 16.17M / 15.42M
- Beta
- —
- Shares outstanding
- 149.04M
52-week range
CYPH stock today
Cypherpunk Technologies (CYPH) closed at $1.41 on Nov 20, down 18.02% (-$0.31), versus the S&P 500's 3.70% decline. At this level, CYPH sits in the middle of its 52-week range of $0.491 to $4.19: 66.3% below the high, set on Sep 25, 2026 and 187.2% above the low. CYPH is up 21.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.2%.
Cypherpunk Technologies trades at 0.7x its trailing twelve-month earnings per share of $2.09.
Summary generated from market data by MetaCap's automated system. Methodology
About Cypherpunk Technologies
Company profileCypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorectal cancer; and FL-501, a monoclonal antibody inhibiting the GDF-15 protein, which is in preclinical development to treat cancer cachexia, hyperemesis gravidarum and pregnancy-related nausea and vomiting, and other diseases associated with aging and frailty.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Douglas E. Onsi J.D.
- Headquarters
- Cambridge, MA
- Employees
- 6
- Website
- cypherpunk.com
Financial highlights
Full financialsNet income was $4.8 million. Diluted earnings per share came in at $0.07.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.50M |
| Growth | — | — | — | — | 0.00% |
| Net income | $4.82M | $-67.56M | $-81.41M | $-54.60M | $-40.59M |
| EPS (diluted) | $0.07 | $-1.81 | $-3.98 | $-4.82 | $-0.47 |
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$5.00+254.61%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.09 vs —
CYPH news
All CYPH news- Cypherpunk (CYPH) Q3 2026 Earnings Call TranscriptNasdaq
- Leap Therapeutics, Inc. Subsidiary Initiates Strategic Process for Sirexatamab and Reports Third Quarter 2026 Financial ResultsNasdaq
- Cypherpunk Technologies to Report Third Quarter 2026 Financial Results on November 16, 2026PR Newswire
- 2 Cryptocurrencies Poised to Surge 100% in the Coming Years That Savvy Investors Are Already BuyingNasdaqUBER, BTC, CYPH
Cypherpunk Technologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs CYPH |
| ARCTArcturus Therapeutics Holdings Inc. | 7.45 | -1.97% | $214.73M | vs CYPH |
| PYXSPyxis Oncology Inc. | 1.81 | +7.74% | $216.49M | vs CYPH |
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs CYPH |
| BCYCBicycle Therapeutics plc ADR | 2.90 | -4.92% | $203.27M | vs CYPH |
| KROSKeros Therapeutics Inc. | 11.08 | -2.72% | $217.44M | vs CYPH |
| RCKTRocket Pharmaceuticals Inc. | 1.95 | -7.58% | $217.74M | vs CYPH |
| IMRXImmuneering Corporation Class A | 3.38 | -2.03% | $218.90M | vs CYPH |
Indexes, lists and sector
Cypherpunk Technologies stock FAQ
What is Cypherpunk Technologies's stock price today?
CYPH last traded at $1.41 as of Nov 20, 4:00 PM EST, down 18.02% on the day. Prices are delayed at least 15 minutes.
Does Cypherpunk Technologies pay a dividend?
No. Cypherpunk Technologies does not currently pay a regular cash dividend.
What is CYPH's P/E ratio?
CYPH trades at a trailing P/E ratio of 0.67.
Who is Cypherpunk Technologies's CEO?
Mr. Douglas E. Onsi J.D. is the chief executive officer of Cypherpunk Technologies Inc., which has about 6 employees.
Has CYPH ever split its stock?
Yes. The most recent CYPH stock split was a 1-for-10 split on Jun 21, 2023.
What is the CYPH 52-week high?
The 52-week high for CYPH is $4.19 and the 52-week low is $0.491. The stock is currently 66.3% below its high.